US EditionPublished • loading... • Updated
Linnaeus Therapeutics awarded up to $22M for age-related treatments
Summary by ROI-NJ
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Linnaeus Therapeutics awarded up to $22M for age-related treatments
Linnaeus Therapeutics, Inc., a privately held company in Haddonfield focused on the development and commercialization of small molecule therapeutics for diseases of aging, announced that it has been awarded a contract of up to $22 million from the Advanced Research Projects Agency for Health (ARPA-H). As part of the PROactive Solutions for Prolonging Resilience (PROSPR) program, Linnaeus will advance its lead drug candidate, LNS8801, for the tre…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
